Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies
Tóm tắt
Từ khóa
Tài liệu tham khảo
Krumbhaar, 1919, The blood and bone marrow in yellow cross gas (mustard gas) poisoning: changes produced in the bone marrow of fatal cases, Journal of Medical Research, 40, 497
Adair, 1931, Experimental and clinical studies on the treatment of cancer by dichloroethylsulphide (mustard gas), Annals of Surgery, 180
Gilman, 1946, The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides, Science, 103, 409, 10.1126/science.103.2675.409
Bergel, 1954, Cyto-active amino-acid and peptide derivatives: Part 1. Substituted phenylalanines, Journal of the Chemical Society, 2409, 10.1039/jr9540002409
Brock, 1967, Pharmacological characterisation of cyclophosphamide (NSC 26 271) and cyclophosphamide metabolites, Cancer Chemotherapy Reports, 51, 315
Springer, 1990, Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2, Journal of Medicinal Chemistry, 33, 677, 10.1021/jm00164a034
Galton, 1953, Myeleran in chronic myeloid leukaemia, Lancet, 264, 208, 10.1016/S0140-6736(53)90885-X
Skinner, 1960, Potential anticancer agents-XXXI. The relationship of chemical structure to antileukemic activity with analogues of 1-methyl-3-nitro-1-nitrosoguanidine (NSC-9369), Journal of Medicinal and Pharmaceutical Chemistry, 2, 299, 10.1021/jm50010a005
Zalupski, 1988, Ifosfamide, Journal of the National Cancer Institute, 80, 556, 10.1093/jnci/80.8.556
Roberts, 1968, The mechanism of the cytotoxic action of alkylating agents in mammalian cells, 5
Tilby, 1990, Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: Characterization of monoalkylated and cross-linked products from reactions of melphalan with dGMP and GMP, Chemico-biological Interactions, 73, 183, 10.1016/0009-2797(90)90002-5
Brookes, 1961, The reaction of mono- and difunctional alkylating agents with nucleic acids, Biochemical Journal, 80, 496, 10.1042/bj0800496
Kohn, 1977, Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitosoureas, Cancer Research, 37, 1450
Pegg, 1990, Mammalian O6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents, Cancer Research, 50, 6119
Kohn, 1976, Fractionation of DNA from mammalian cells by alkaline elution, Biochemistry, 15, 4629, 10.1021/bi00666a013
Seaman, 1966, Antibodies to the methylene blue sensitized photooxidation of deoxyribonucleic acid, Biochemistry, 5, 1216, 10.1021/bi00868a015
Tilby, 1987, Immonological detection of DNA damage caused by melphalan using monoclonal antibodies, Cancer Research, 47, 1542
Tilby, 1992
Mustonen, 1991, Measurement of 32P-post-labelling of 7-methylguanine levels in white blood cell DNA of healthy individuals and cancer patients treated with dacarbazine and procarbazine. Human data and method development for 7-alkylguanines, Carcinogenesis, 12, 1423, 10.1093/carcin/12.8.1423
Rhoads, 1992, Nitrogen mustards in the treatment of neoplastic diseases, Journal of the American Medical Association, 131, 656, 10.1001/jama.1946.02870250010003
Goldie, 1979, A mathmatical model for relating the drug sensitivity of tumors to their spontaneous mutation rate, Cancer Treatment Reports, 63, 1727
Foon, 1986, Principles of leukemia treatment, 1
Shapiro, 1984, Clonal tumour cell heterogeneity, Progress in Experimental Tumor Research, 27, 49, 10.1159/000408222
Durie, 1984, Is myeloma really a monoclonal disease?, British Journal of Haematology, 57, 357, 10.1111/j.1365-2141.1984.tb02909.x
Sviland, 1987, Short course intermediate dose intravenous melphalan therapy in myeloma-relation to emergence of drug resistance (phase II study), Acta Haematologica, 78, 233, 10.1159/000205884
Teicher, 1990, Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo, Science, 247, 1457, 10.1126/science.2108497
Brox, 1979, Pharmacology of intravenous melphalan in patients with multiple myeloma, Cancer Treatment Reviews, 6, 27, 10.1016/S0305-7372(79)80007-9
Alberts, 1979, Oral melphalan kinetics, Clinical Pharmacology and Therapeutics, 26, 737, 10.1002/cpt1979266737
Alberts, 1980, Comparative pharmacokinetics of chlorambucil and melphalan in man, Recent Results in Cancer Research, 74, 124, 10.1007/978-3-642-81488-4_16
Struck, 1987, Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administrationi in a randomized crossover trial, Cancer Research, 47, 2723
McLean, 1979, Pharmacokinetics and metabolism of chlorambucil in patients with malignant disease, Cancer Treatment Reviews, 6, 33, 10.1016/S0305-7372(79)80008-0
Colvin, 1988, Enzymatic mechanisms of resistance to alkylating agents in tumor cells and normal tissues, Advances in Enzyme Regulation, 27, 211, 10.1016/0065-2571(88)90018-0
Jao, 1972, Phenobarbital effects on cyclophosphamide pharmacokinetics in man, Cancer Research, 32, 2761
D'Incalci, 1979, Decreased half-life of cyclophosphamide in patients under continual treatment, European Journal of Cancer, 15, 7, 10.1016/0014-2964(79)90198-1
Levin, 1979, The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo)-3-piperidy-1-nitrosourea (PCNU) and on the plasma pharmacokinetics and biotransformation of BCNU, Journal of Pharmacology and Experimental Therapeutics, 208, 1
Smith, 1989, Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells, Cancer Research, 49, 2621
Bird, 1988, Long-term comparison of results of a drug sensitivity assay in vitro with patient response in lymphatic neoplasms, Cancer, 61, 1104, 10.1002/1097-0142(19880315)61:6<1104::AID-CNCR2820610609>3.0.CO;2-6
Chan, 1990, Immunohistochemical detection of P-Glycoprotein: prognostic correlation in soft tissue sarcoma of childhood, Journal of Clinical Oncology, 8, 689, 10.1200/JCO.1990.8.4.689
Begleiter, 1979, Evidence for active transport of melphalan by two amino acid carriers in L5178Y lymphoblasts in vitro, Cancer Research, 39, 353
Redwood, 1980, Transport of melphalan by sensitive and resistant L1210 cells, Cancer Research, 40, 1144
Vistica, 1980, Cytotoxicity as an indicator for transport mechanism: evidence that murine bone marrow progenitor cells lack a high-affinity leucine carrier that transports melphalan in murine L1210 leukemia cells, Blood, 56, 427, 10.1182/blood.V56.3.427.427
Beck, 1991, Characteristics of multidrug resistance in human tumor cells, 3
Sugimoto, 1991, Development of multidrug resistance in rodent cell lines, 57
Ling, 1974, Reduced permeability in Chinese hamster ovary cells as a mechanism of resistance to colchicine, Journal of Cellular Physiology, 83, 103, 10.1002/jcp.1040830114
Juliano, 1976, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochimica et Biophysica Acta, 455, 152, 10.1016/0005-2736(76)90160-7
Hagenbeek, 1987, In vivo development of cytosine arabinoside resistance in the BN acute myelocytic leukemia, 14, 202
Dulik, 1986, Characterization of melphalan-glutathione adducts whose formation is catalyzed by glutathione transferases, Biochemical Pharmacology, 35, 3405, 10.1016/0006-2952(86)90444-2
Bosanquet, 1988, Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays, Cancer Chemotherapy and Pharmacology, 21, 211, 10.1007/BF00262772
Suzukake, 1982, Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity, Biochemical Pharmacology, 31, 121, 10.1016/0006-2952(82)90249-0
Somfai Relle, 1984, Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard, Biochemical Pharmacology, 33, 485, 10.1016/0006-2952(84)90245-4
Robson, 1987, Reduced levels of drug-induced DNA cross-linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione S-transferase activity, Cancer Research, 47, 6022
Gupta, 1989, Glutathione and glutathione S-transferases in a human plasma cell line resistant to melphalan, Biochemical Pharmacology, 38, 1993, 10.1016/0006-2952(89)90499-1
Evans, 1987, Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard, Cancer Research, 47, 2525
Wang, 1985, Increased glutathione s-transferase activity in a cell line with acquired resistance to nitrogen mustards, Cancer Treatment Reports, 69, 677
Clapper, 1987, Glutathione S-transferases in alkylating agent resistant cells, 213
Hall, 1989, Possible role of inhibition of glutathione S-transferase in the partial reversal of chlorambucil resistance by indomethacin in a Chinese hamster ovary cell line, Cancer Research, 49, 6265
Tew, 1988, Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines, Cancer Research, 48, 3622
Moscow, 1989, Elevation of pi class glutathione S-transferase activity in human breast cancer cells by transfection of the GST pi gene and its effect on sensitivity to toxins, Molecular Pharmacology, 36, 22
Leyland Jones, 1991, Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human alpha class glutathione S-transferase gene, Cancer Research, 51, 587
Puchalski, 1990, Expression of recombinant glutathione S-transferase π, Ya, or Yb1 confers resistance to alkylating agents, 87, 2443
Bolton, 1991, Specificity of isozymes of murine hepatic glutathione S-transferase for the conjugation of glutathione with L-phenylalanine mustard, Cancer Research, 51, 2410
Hall, 1990, Purification and characterization of a pi class glutathione S-transferase from human leukaemic cells, British Journal of Haematology, 76, 494, 10.1111/j.1365-2141.1990.tb07906.x
Eastman, 1990, Activation of programmed cell death by anti-cancer agents: cisplatin as a model system, Cancer Cells, 2, 275
Anilkumar, 1992, The nature of cytotoxic drug-induced cell death in murine intestinal crypts, British Journal of Cancer, 65, 552, 10.1038/bjc.1992.113
Wyllie, 1980, Cell death: the significance of apoptosis, International Review of Cytology, 68, 251, 10.1016/S0074-7696(08)62312-8
Haskell, 1969, L-Asparaginase resistance in human leukaemia-asparagine synthetase, Biochemical Pharmacology, 18, 2578, 10.1016/0006-2952(69)90375-X
Horowitz, 1968, Asparagine synthetase activity of mouse leukemia, Science, 160, 533, 10.1126/science.160.3827.533
Nunberg, 1978, Amplified dihydrofolate reductase genes are localized to a homogeneously staining region of a single chromosome in a methotrexate resistant Chinese hamster ovary cell line, 75, 5553
Jackson, 1977, Acquired methotrexate resistance in lymphoblasts resulting from altered kinetic properties of dihydrofolate reductase, European Journal of Cancer, 13, 567, 10.1016/0014-2964(77)90118-9
Bank, 1989, Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes, Cancer Research, 49, 554
Evans, 1989, Clinical pharmacokinetics-pharmacodynamics of anticancer drugs, Clinical Pharmacokinetics, 16, 327, 10.2165/00003088-198916060-00001
Rosenberg, 1989, Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion, Cancer Research, 49, 6917